ATE342959T1 - System und verfahren zum optimieren des gewebebarrieretransfers von verbindungen - Google Patents

System und verfahren zum optimieren des gewebebarrieretransfers von verbindungen

Info

Publication number
ATE342959T1
ATE342959T1 AT01955832T AT01955832T ATE342959T1 AT E342959 T1 ATE342959 T1 AT E342959T1 AT 01955832 T AT01955832 T AT 01955832T AT 01955832 T AT01955832 T AT 01955832T AT E342959 T1 ATE342959 T1 AT E342959T1
Authority
AT
Austria
Prior art keywords
methods
tissue barrier
transfer
throughput
barrier transfer
Prior art date
Application number
AT01955832T
Other languages
English (en)
Inventor
Michael J Cima
Hongming Chen
J Richard Gyory
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE342959T1 publication Critical patent/ATE342959T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5025—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures for parallel transport of multiple samples
    • B01L3/50255—Multi-well filtration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
AT01955832T 2000-07-14 2001-07-13 System und verfahren zum optimieren des gewebebarrieretransfers von verbindungen ATE342959T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21837700P 2000-07-14 2000-07-14
US22032400P 2000-07-24 2000-07-24
US24089100P 2000-10-16 2000-10-16

Publications (1)

Publication Number Publication Date
ATE342959T1 true ATE342959T1 (de) 2006-11-15

Family

ID=27396536

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01955832T ATE342959T1 (de) 2000-07-14 2001-07-13 System und verfahren zum optimieren des gewebebarrieretransfers von verbindungen

Country Status (9)

Country Link
US (2) US6758099B2 (de)
EP (1) EP1301619B1 (de)
JP (1) JP2004504585A (de)
AT (1) ATE342959T1 (de)
AU (2) AU7788701A (de)
DE (1) DE60123960T2 (de)
ES (1) ES2273873T3 (de)
IL (2) IL153468A0 (de)
WO (1) WO2002006518A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182293A1 (en) * 2000-07-14 2008-07-31 Transform Pharmaceuticals, Inc. Computerized control of high-throughput transdermal experimental processing and digital analysis of comparative samples
US7172859B2 (en) 2000-07-14 2007-02-06 Transform Pharmaceuticals, Inc. System and method for optimizing tissue barrier transfer of compounds
US6852526B2 (en) 2000-07-14 2005-02-08 Transform Pharmaceuticals, Inc. Transdermal assay with magnetic clamp
DE60123960T2 (de) 2000-07-14 2007-04-26 Transform Pharmaceuticals, Inc., Lexington System und verfahren zum optimieren des gewebebarrieretransfers von verbindungen
US20040023841A1 (en) * 2001-08-23 2004-02-05 Samir Mitragotri Combinatorial method for rapid screening of drug delivery formulations
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
EP1556501A4 (de) * 2002-10-28 2009-04-08 Transform Pharmaceuticals Inc Transdermaler assay mit magnetischerklemme
US7449307B2 (en) 2002-10-28 2008-11-11 Transform Pharmaceuticals, Inc. Raised surface assay plate
US6908760B2 (en) * 2002-10-28 2005-06-21 Transform Pharmaceuticals, Inc. Raised surface assay plate
US20060141443A1 (en) * 2003-01-21 2006-06-29 Gyory J R Apparatus and method for transcellular testing
CA2467131C (en) * 2003-05-13 2013-12-10 Becton, Dickinson & Company Method and apparatus for processing biological and chemical samples
CA2530407A1 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
US7635452B2 (en) * 2003-09-24 2009-12-22 3M Innovative Properties Company System, kit, and method for measuring membrane diffusion
US20050065062A1 (en) * 2003-09-24 2005-03-24 3M Innovative Properties Company Method of formulating a pharmaceutical composition
US6844545B1 (en) * 2003-10-10 2005-01-18 Perseptive Biosystems, Inc. MALDI plate with removable insert
US20050265902A1 (en) * 2004-05-27 2005-12-01 Ellen Chen Industry standard multi-well plates with increased capacity and efficiency per well
US20100239655A1 (en) * 2004-12-09 2010-09-23 Georgia Levis Taurine-based compositions and therapeutic methods
US7856263B2 (en) * 2005-04-22 2010-12-21 Travanti Pharma Inc. Transdermal systems for the delivery of therapeutic agents including granisetron using iontophoresis
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
WO2008115224A2 (en) * 2007-03-20 2008-09-25 Bayer Healthcare Llc Method of analyzing an analyte
CA2696227A1 (en) * 2007-10-17 2009-04-23 Transpharma Medical Ltd. Dissolution rate verification
TWI398307B (zh) * 2009-07-09 2013-06-11 Chan Li Machinery Co Ltd Detection and screening device and its detection and screening method
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
AU2010339689B2 (en) * 2010-01-07 2015-02-19 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
WO2015020614A1 (en) * 2013-08-07 2015-02-12 Agency For Science, Technology And Research Methods, apparatuses, and systems for cell and tissue culture
CA3050082A1 (en) 2016-04-04 2017-10-12 Omeza LLC Fish oil topical composition
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
FI127408B (en) 2016-09-29 2018-05-15 Nanoform Finland Oy Device, method and equipment for solubility testing
EP3399313A1 (de) * 2017-05-03 2018-11-07 Galderma Research & Development Vorrichtung und verfahren zur messung der diffusion einer verbindung über einer membran
US20210072231A1 (en) * 2019-09-09 2021-03-11 Board Of Regents, The University Of Texas System Methods and apparatus for high-throughput screening for testing permeability and retention of compounds across biological barriers
CN113567690A (zh) * 2020-04-28 2021-10-29 深圳迎凯生物科技有限公司 孵育组件、孵育装置和自动分析装置
DE102021114585A1 (de) 2021-06-07 2022-12-08 Leica Microsystems Cms Gmbh Mikrotiterplatte, Komponenten hierfür, Probentisch, Mikroskop und entsprechendes Verfahren

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3893891A (en) * 1973-06-14 1975-07-08 New Brunswick Scientific Co Multiple diffusion chamber
US4045291A (en) 1976-07-15 1977-08-30 Berger Jacob E Tissue specimen container
FR2391467A1 (fr) 1977-05-20 1978-12-15 Anvar Cellule de mesure pour microdosages, comprenant des electrodes a membranes enzymatiques
US4317726A (en) 1981-02-12 1982-03-02 The United States Of America As Represented By The Secretary Of The Army Microbial filter assembly
US4468321A (en) 1982-03-12 1984-08-28 Gelman Sciences Inc. Filter device with magnetic filter clamp
US4686190A (en) * 1986-02-19 1987-08-11 The Research Foundation Of State University Of New York Device useful for growing and/or testing biological materials
US4771004A (en) * 1986-08-29 1988-09-13 Iprx, Inc. Method for in vitro determination of transdermal absorption
US4667504A (en) * 1986-10-02 1987-05-26 The United States Of America As Represented By The Secretary Of The Air Force Flow through device for determination of the penetration rate of chemicals across biological membranes in vitro
US4835102A (en) * 1987-03-31 1989-05-30 Eugene Bell Tissue equivalent test systems
US4863696A (en) * 1987-08-03 1989-09-05 Crown Glass Company, Inc. Apparatus for the percutaneous absorption of fluids
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4912060A (en) * 1989-02-17 1990-03-27 World Precision Instruments, Inc. Method and apparatus for electrical testing of membranes
US4912057A (en) 1989-06-13 1990-03-27 Cancer Diagnostics, Inc. Cell chamber for chemotaxis assay
JPH0389146A (ja) * 1989-08-31 1991-04-15 Shiseido Co Ltd 経皮吸収評価装置
US5306467A (en) 1993-02-17 1994-04-26 Hamilton-Thorn Research Apparatus for measurement of cell concentration in a biological sample employing a magnetic slide loading apparatus
JPH07126190A (ja) * 1993-11-01 1995-05-16 Pola Chem Ind Inc 経皮吸収抑制剤及びこれを含有する皮膚外用剤
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5490415A (en) * 1994-04-15 1996-02-13 Pharmetrix Corporation Diffusion test apparatus and method
US5503843A (en) 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5695998A (en) * 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US6002961A (en) 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
US6041253A (en) 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
US5947921A (en) 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
IL115390A (en) 1995-09-21 2001-07-24 Abdulrazik Mohammad Diffusion cell for ex-vivo pressure-controlled transcorneal drug penetration studies
JP2002515786A (ja) 1996-06-28 2002-05-28 ソントラ メディカル，エル．ピー． 経皮輸送の超音波増強
US5962250A (en) * 1997-10-28 1999-10-05 Glaxo Group Limited Split multi-well plate and methods
JPH11199436A (ja) * 1998-01-05 1999-07-27 Pola Chem Ind Inc 敏感肌用の化粧料の鑑別法
CA2317777C (en) 1998-01-08 2005-05-03 Sontra Medical, Inc. Sonophoretic enhanced transdermal transport
GB9812783D0 (en) * 1998-06-12 1998-08-12 Cenes Ltd High throuoghput screen
DE60123960T2 (de) 2000-07-14 2007-04-26 Transform Pharmaceuticals, Inc., Lexington System und verfahren zum optimieren des gewebebarrieretransfers von verbindungen
WO2002016941A2 (en) 2000-08-23 2002-02-28 The Regents Of The University Of California A combinatorial method for rapid screening of drug delivery formulations

Also Published As

Publication number Publication date
US20040087007A1 (en) 2004-05-06
AU2001277887B2 (en) 2006-09-14
IL153468A (en) 2008-07-08
US20020025509A1 (en) 2002-02-28
ES2273873T3 (es) 2007-05-16
EP1301619A1 (de) 2003-04-16
DE60123960D1 (de) 2006-11-30
EP1301619A4 (de) 2005-06-01
JP2004504585A (ja) 2004-02-12
AU7788701A (en) 2002-01-30
WO2002006518A1 (en) 2002-01-24
EP1301619B1 (de) 2006-10-18
US6758099B2 (en) 2004-07-06
IL153468A0 (en) 2003-07-06
DE60123960T2 (de) 2007-04-26

Similar Documents

Publication Publication Date Title
DE60123960D1 (de) System und verfahren zum optimieren des gewebebarrieretransfers von verbindungen
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
BR0009721A (pt) Inibidores de tirosina quinase de proteìna cìclica
NO20002133L (no) Oppløsninger og dispersjoner i fast tilstand av svakt vannoppløselige legemidler
BR0306785A (pt) Deazapurinas e seus usos
DE69716449D1 (de) Substituierte zyklische amine als metalloproteaseinhibitoren
BR0013200A (pt) Compostos derivados de heterobiciclos contendo nitrogênio, composições farmacêuticas, método de tratamento ou prevenção de uma disfunção tromboembólica e uso dos compostos
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
TR200103428T2 (tr) IMPDH enzim inhibitörleri.
CY1108012T1 (el) Εγχεομενες στερεες ραβδοι και παστες φωσφορικου ασβεστιου για απελευθερωση οστεογονικων πρωτεϊνων
CO5631443A2 (es) Derivados de 7-aril-3,9-diazabiciclo (3.3.1) non-6-eno y su uso como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales
AR024138A1 (es) Inhibidores de la proliferacion celular
NO20084186L (no) Nye aminer
BRPI0309651B8 (pt) método para prevenir ou reduzir a resistência a um pesticida de uma peste de substrato, composição de pesticida, uso dos mesmos, e, método para preparar uma composição de pesticida
AU2003285143A8 (en) Analysis of pharmaceutical solubility and stability
HUP0300653A2 (hu) Herbicid hatóanyagot tartalmazó folyékony készítmények előállítása és alkalmazása
BR112023025235A2 (pt) Compostos de indol substituídos e métodos de uso dos mesmos
BR0306928A (pt) Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace)
IS2369B (is) Ný blanda 5-HT4 gerandefna eða mótlyfja til inntöku um munn
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
BR0310003A (pt) compostos peptìdeos e seu uso como substratos de protease
NO20084055L (no) Nye primaere aminer
ATE401913T1 (de) Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation
ATE305921T1 (de) Neue analoga von 16-hydroxyeicosatetraensäure
AU1092800A (en) N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1301619

Country of ref document: EP

REN Ceased due to non-payment of the annual fee